Dr. Cafri specialized in tumor immunology and cancer immunotherapy. For the last 20 years, Dr. Cafri has studied the interactions between tumors and the immune system. He began his career working on chimeric molecules to enhance vaccine activity against skin cancer at the Weizmann Institute of Science. Later, Dr. Cafri spent 5 years at the National Cancer Institute (NCI) in Bethesda, Maryland, specializing in treating patients with immune cells directed against cancer mutations. While at the NCI, Dr. Cafri was responsible for developing two clinical trials to vaccinate cancer patients with their tumor mutations. Dr. Cafri's lab at Sheba Medical Center develops T-cell receptor therapy for patients with common epithelial cancers and infectious diseases, and innovative mRNA engineering approaches to reprogram human T-cells and monocytes.